GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Neuronetics Inc (NAS:STIM) » Definitions » Change In Receivables
中文

Neuronetics (Neuronetics) Change In Receivables

: $-8.83 Mil (TTM As of Dec. 2023)
View and export this data going back to 2018. Start your Free Trial

Neuronetics's change in receivables for the quarter that ended in Dec. 2023 was $-0.90 Mil. It means Neuronetics's Accounts Receivable increased by $0.90 Mil from Sep. 2023 to Dec. 2023 .

Neuronetics's change in receivables for the fiscal year that ended in Dec. 2023 was $-8.83 Mil. It means Neuronetics's Accounts Receivable increased by $8.83 Mil from Dec. 2022 to Dec. 2023 .

Neuronetics's Accounts Receivable for the quarter that ended in Dec. 2023 was $15.78 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Neuronetics's Days Sales Outstanding for the three months ended in Dec. 2023 was 70.89.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Neuronetics's liquidation value for the three months ended in Dec. 2023 was $-5.18 Mil.


Neuronetics Change In Receivables Historical Data

The historical data trend for Neuronetics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neuronetics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Receivables
Get a 7-Day Free Trial -0.95 -0.60 -3.82 -6.66 -8.83

Neuronetics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.07 -2.01 -3.45 -2.48 -0.90

Neuronetics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.83 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neuronetics  (NAS:STIM) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Neuronetics's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=15.782/20.314*91
=70.89

2. In Ben Graham's calculation of liquidation value, Neuronetics's accounts receivable are only considered to be worth 75% of book value:

Neuronetics's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=60.582-81.641+0.75 * 15.782+0.5 * 8.093
=-5.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neuronetics Change In Receivables Related Terms

Thank you for viewing the detailed overview of Neuronetics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Neuronetics (Neuronetics) Business Description

Traded in Other Exchanges
Address
3222 Phoenixville Pike, Malvern, PA, USA, 19355
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.
Executives
Keith J Sullivan director, officer: President and CEO C/O RELIANT TECHNOLOGIES, INC., 464 ELLIS STREET, MOUNTAIN VIEW CA 94043
William Andrew Macan officer: Sr. VP, GC, CCO and Secretary 24275 KATY FREEWAY, SUITE 600, KATY TX 77494
Stephen Furlong officer: CFO C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Robert Cascella director C/O HOLOGIC, INC., BEDFORD MA 01730
John K Bakewell director C/O LANTHEUS MEDICAL IMAGING, INC., 331 TREBLE COVE ROAD, NO. BILLERICA MA 01862
Cannell Capital Llc 10 percent owner 245 MERIWETHER CIRCLE, ALTA WY 83414
Joseph H Capper director BIOTELEMETRY, INC., 1000 CEDAR HOLLOW ROAD, #102, MALVERN PA 19355
Bruce Joseph Shook director 162 CRICKET AVE, ARDMORE PA 19003
Megan Rosengarten director C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Sheryl L Conley director C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Wilfred E Jaeger director C/O THREE ARCH PARTNERS, 3200 ALPINE RD, PORTOLA VALLEY CA 94028
Glenn P Muir director C/O HOLOGIC, INC., BEDFORD MA 01730
Gregory Harper officer: VP of Prod. Dev. & Operations C/O NEURONETICS, INC, 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Brian E Farley director 2200 ZANKER ROAD, SUITE F, SAN JOSE CA 95131
Daniel Guthrie officer: Chief Commercial Officer C/O NEURONETICS, INC, 322 PHOENIXVILLE PIKE, MALVERN PA 19355